Loading the security overview…
Where the tokens are
| Quarter | Reported | EPS | EPS vs year ago | Revenue | Revenue vs year ago | Consensus EPS |
|---|---|---|---|---|---|---|
| Q2 FY26ended Jun 30, 2026 | Aug 11, 2026 | −$0.05 | — | $0 | — | −$0.04 |
| Q1 FY26ended Mar 31, 2026 | May 19, 2026 | −$0.05 | — | $0 | — | −$0.06 |
| Q4 FY25ended Dec 31, 2025 | — | −$0.05 | — | $0 | — | — |
| Q3 FY25ended Sep 30, 2025 | — | −$0.06 | — | — | — | — |
| Q2 FY25ended Jun 30, 2025 | — | −$0.07 | — | $0 | — | — |
| Q1 FY25ended Mar 31, 2025 | — | −$0.07 | — | $0 | — | — |
| Q4 FY24ended Dec 31, 2024 | — | −$0.09 | — | $0 | — | — |
| Q3 FY24ended Sep 30, 2024 | — | −$0.10 | — | — | — | — |
| Q2 FY24ended Jun 30, 2024 | — | −$0.13 |
Growth compares each quarter with the same fiscal quarter a year earlier, and is left blank where that quarter is missing or its figure was zero or a loss. Consensus is the estimate published before each report. It usually refers to adjusted EPS, so it is shown beside the GAAP figure rather than subtracted from it: the difference would not be a beat or a miss.
Figures describe SELLAS Life Sciences shares, not any token. As of Aug 11, 2026, from Massive's standardised financials and the earnings calendar.
| — |
| — |
| — |
| — |
| Q1 FY24ended Mar 31, 2024 | — | −$0.21 | — | — | — | — |
| Q4 FY23ended Dec 31, 2023 | — | −$0.25 | — | — | — | — |
| Q3 FY23ended Sep 30, 2023 | — | −$0.33 | — | — | — | — |